financetom
Business
financetom
/
Business
/
Russia and Eurasian Union agree high-sulphur bunker fuel usage to 2026
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Russia and Eurasian Union agree high-sulphur bunker fuel usage to 2026
Apr 24, 2024 4:50 AM

MOSCOW, April 24 (Reuters) - Russia and its partners

inside the Eurasian Economic Union (EEU) have agreed to continue

high-sulphur bunker fuel usage and production for vessels inside

the bloc until the end of 2026, the Eurasian Economic Commission

(EEC) said on its website.

The International Maritime Organization (IMO), of which

Russia is a member, implemented a 0.5% sulphur content limit for

bunker fuel internationally from 2020, in one of main changes

for the marine industry in recent years.

However, the EEU has been slow to implement the limit for

its domestic water-borne transport, which allows its refineries

to continue high-sulphur fuel sales.

"Until the end of 2026, for vessels involved in

transportation inside the Union, production of bunker fuel with

sulphur content of 1.5% has been allowed to continue", the EEC

said in its statement.

The EEC is a legal authority acting inside the EEU which

includes Russia, Kazakhstan, Kyrgyzstan, Armenia and Belarus.

Initially, bunker fuel output and use inside the EEU was

expected to be limited to only 0.5% sulphur content from the

beginning of 2024 in line with international standards.

The recent change in EEU regulations was implemented by the

EEC at the end of November 2023.

Russia and the EEU, which were initially expected to

implement the same change for inland waters, said the

regulations would be postponed for three years.

The latest postponement to the sulphur content limit

regulation for bunker fuel, marks the second such delay by

Russia and the EEU to the regulations.

The EEC said the rules were amended after a Russian proposal

to guarantee stable functioning of local logistics schemes,

including supplying goods to regions like the Far North.

Russia's Ministry of Transport did not respond to a Reuters

request for a comment.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Biohaven Says BHV-1300 Achieves 'Deep Lowering' of Targeted IgG During Early-Stage Trial
Biohaven Says BHV-1300 Achieves 'Deep Lowering' of Targeted IgG During Early-Stage Trial
Dec 16, 2024
08:32 AM EST, 12/16/2024 (MT Newswires) -- Biohaven ( BHVN ) said Monday that its drug candidate BHV-1300 achieved deep lowering of targeted immunoglobulin G, or IgG, with reduction of more than 60% in the lowest subcutaneous dose tested during the current multiple ascending dose trial. The biopharmaceutical company said that the reduction in IgG occurred within hours of each...
Berkshire Hills Bancorp and Brookline to merge in $1.1 bln deal
Berkshire Hills Bancorp and Brookline to merge in $1.1 bln deal
Dec 16, 2024
Dec 16 (Reuters) - Regional lenders Berkshire Hills Bancorp ( BHLB ) and Brookline Bancorp ( BRKL ) have agreed to merge in an all-stock deal valued at about $1.1 billion, the companies said on Monday. ...
Gatos Silver, First Majestic Get Regulatory Approval for Merger
Gatos Silver, First Majestic Get Regulatory Approval for Merger
Dec 16, 2024
08:32 AM EST, 12/16/2024 (MT Newswires) -- Gatos Silver ( GATO ) said Friday that the proposed acquisition of the company by First Majestic (AG) was given unconditional authorization by the Mexican Federal Economic Competition Commission. The transaction is expected to close in January. ...
Mind Medicine Doses First Patient in Phase 3 Study of MM120 to Treat Generalized Anxiety Disorder
Mind Medicine Doses First Patient in Phase 3 Study of MM120 to Treat Generalized Anxiety Disorder
Dec 16, 2024
08:35 AM EST, 12/16/2024 (MT Newswires) -- Mind Medicine (MNMD) said Monday that a first patient has been dosed in its phase 3 Voyage study that is evaluating MM120 ODT for the treatment of generalized anxiety disorder. The company said the trial is the first of two phase 3 studies evaluating the efficacy and safety of MM120 ODT versus placebo....
Copyright 2023-2025 - www.financetom.com All Rights Reserved